Meag Munich Ergo Kapitalanlagegesellschaft MBH Reduces Stake in Pfizer, Inc. (PFE)
Meag Munich Ergo Kapitalanlagegesellschaft MBH cut its stake in Pfizer, Inc. (NYSE:PFE) by 41.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 143,712 shares of the biopharmaceutical company’s stock after selling 103,198 shares during the quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH’s holdings in Pfizer were worth $4,824,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently bought and sold shares of PFE. Asset Planning Services Ltd. increased its stake in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 137 shares during the last quarter. D. Scott Neal Inc. increased its position in Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the last quarter. Orrstown Financial Services Inc. increased its position in Pfizer by 23.0% during the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC acquired a new position in Pfizer during the first quarter worth $121,000. Finally, Cascade Investment Advisors Inc. increased its position in Pfizer by 89.1% during the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 2,200 shares during the last quarter. 69.09% of the stock is currently owned by institutional investors and hedge funds.
Several equities analysts have commented on the stock. Berenberg Bank reissued a “hold” rating and set a $36.00 target price (down from $39.00) on shares of Pfizer in a research report on Tuesday, August 15th. BMO Capital Markets reissued a “buy” rating and set a $37.00 target price on shares of Pfizer in a research report on Thursday. BidaskClub raised shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 5th. Vetr downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price on the stock. in a research report on Wednesday. Finally, Cowen and Company set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $37.72.
COPYRIGHT VIOLATION WARNING: This news story was first published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/09/14/meag-munich-ergo-kapitalanlagegesellschaft-mbh-reduces-stake-in-pfizer-inc-pfe.html.
Pfizer, Inc. (NYSE PFE) traded up 2.0037% during midday trading on Thursday, hitting $35.7625. 14,128,502 shares of the company traded hands. The stock’s 50-day moving average price is $33.44 and its 200 day moving average price is $33.49. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $35.84. The company has a market capitalization of $212.69 billion, a price-to-earnings ratio of 26.1613 and a beta of 1.00.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. Pfizer’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.64 EPS. On average, equities analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were paid a dividend of $0.32 per share. The ex-dividend date was Wednesday, August 2nd. This represents a $1.28 annualized dividend and a dividend yield of 3.65%. Pfizer’s dividend payout ratio is presently 94.12%.
In other news, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the transaction, the insider now directly owns 151,474 shares in the company, valued at approximately $5,074,379. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $34.00, for a total transaction of $249,900.00. Following the transaction, the insider now owns 132,124 shares in the company, valued at $4,492,216. The disclosure for this sale can be found here. Insiders have sold a total of 464,521 shares of company stock worth $15,813,961 over the last 90 days. 0.06% of the stock is owned by company insiders.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.